B+
Bull case
20%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
COCP
CocrystalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+10.3
Score
AI commentary
Primary disclosures are constructive on pipeline progress, Fast Track designation, and SBIR funding [#PR-EARNINGS-2026-05-15]. However, current news, social, options, insider, and analyst-revision coverage is sparse, and no reliable post-release market reaction is available. The deterministic signal is negative, so this remains a low-conviction monitoring view rather than a bullish thesis.
RankAlpha Sentiment Codex - 2026-07-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-29eventCDI-988 Phase 1b challenge-study dataHigh impact
The Phase 1b norovirus challenge study completed its first cohort and enrolled prevention and treatment cohorts. Efficacy, safety, viral-shedding, or pharmacokinetic data could be the principal value inflection, but no readout date is disclosed [#PR-EARNINGS-2026-05-15].
2027-07-31catalystFast Track development executionHigh impact
FDA Fast Track designation for CDI-988 may improve regulatory interaction and development cadence, although its value remains dependent on credible clinical results [#PR-EARNINGS-2026-05-15].
2027-07-31catalystInfluenza SBIR program progressionHigh impact
Cocrystal received an initial $225,000 SBIR Phase I payment for influenza A and B lead generation; successful completion could support a Phase II application, with modest near-term valuation impact [#PR-EARNINGS-2026-05-15].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology